Literature DB >> 29678811

Clinical Inertia in Type 2 Diabetes Management: Evidence From a Large, Real-World Data Set.

Kevin M Pantalone1, Anita D Misra-Hebert2,3, Todd M Hobbs4, Xinge Ji3, Sheldon X Kong5, Alex Milinovich3, Wayne Weng5, Janine Bauman3, Rahul Ganguly5, Bartolome Burguera6,7, Michael W Kattan3, Robert S Zimmerman6.   

Abstract

Entities:  

Year:  2018        PMID： 29678811     DOI： 10.2337/dc18-0116

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  23 in total

1.  Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes.

Authors:  David C Klonoff; Alberto Gutierrez; Alexander Fleming; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2019-04-03

2.  Evaluation of a Pharmacist-Managed Medication Adjustment Clinic Within an Academic Endocrinology Practice.

Authors:  Margaret C Schaefer; Kristina W Naseman; Aric D Schadler
Journal:  Diabetes Spectr       Date:  2022-02-02

3.  The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model.

Authors:  Kevin M Pantalone; Anita D Misra-Hebert; Todd M Hobbs; Sheldon X Kong; Xinge Ji; Rahul Ganguly; Alex Milinovich; Wayne Weng; Janine M Bauman; Paul Petraro; Bartolome Burguera; Robert S Zimmerman; Michael W Kattan
Journal:  Diabetes Care       Date:  2020-06-11       Impact factor: 19.112

4.  Long-Term Patterns of Antidiabetic Medication Use in Patients with Type 2 Diabetes.

Authors:  Yang Xu; Zhirong Yang; Hongbo Lin; Peng Shen; Haining Wang; Siyan Zhan
Journal:  Med Sci Monit       Date:  2018-12-02

5.  What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study.

Authors:  Andrew P McGovern; John M Dennis; Beverley M Shields; Andrew T Hattersley; Ewan R Pearson; Angus G Jones
Journal:  BMC Med       Date:  2019-04-12       Impact factor: 8.775

6.  Individualised targets for insulin initiation in type 2 diabetes mellitus-the influence of physician and practice: a cross-sectional study in eight European countries.

Authors:  Anne Meike Boels; Elwin Koning; Rimke C Vos; Kamlesh Khunti; Guy Ehm Rutten
Journal:  BMJ Open       Date:  2019-08-26       Impact factor: 2.692

Review 7.  Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.

Authors:  Jennifer Okemah; John Peng; Manuel Quiñones
Journal:  Adv Ther       Date:  2018-10-29       Impact factor: 3.845

8.  Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.

Authors:  Juan P Frias; Zachary Zimmer; Raymond L H Lam; Guillermo Amorin; Catherine Ntabadde; Carol Iredale; Edward A O'Neill; Samuel S Engel; Keith D Kaufman; Hideo Makimura; Michael F Crutchlow
Journal:  Diabetes Obes Metab       Date:  2019-02-17       Impact factor: 6.577

9.  Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.

Authors:  Barnaby Hunt; Brian B Hansen; Åsa Ericsson; Klaus Kallenbach; Sarah N Ali; Tam Dang-Tan; Samuel J P Malkin; William J Valentine
Journal:  Adv Ther       Date:  2019-10-24       Impact factor: 3.845

Review 10.  Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.

Authors:  Stewart Harris; Martin J Abrahamson; Antonio Ceriello; Guillaume Charpentier; Marc Evans; Roger Lehmann; Andreas Liebl; Sultan Linjawi; Richard I G Holt; Nóra Hosszúfalusi; Guy Rutten; Tina Vilsbøll
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.